Clinical Trial Update: Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer [Phase 3]

View source ↗

Summary

A completed Phase 3 safety and efficacy trial evaluating Leuprolide Acetate Injectable Suspension 22.5 mg for the treatment of prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprolide Acetate Injectable Suspension 22.5 mg (Leuprolide acetate)

Snippet

Sponsor: Oakwood Laboratories, LLC | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED